So, P 2/3 trial to cost up $20m to $30m. for the full trial.
But, we are looking at a readout at halfway point to support accelerated approval.
Is it fair to say that PAA could get away with circa $15m additional funding from here (on top of the circa $5m as at 31 Dec). To the initial readout.
Less the $1.8m from FightMND. Then we will need about $13m. I note we had 1.1m Dec 2025 options exercised, that is about $200k....
Also seems that the comments re some larger shareholders exercising other options series early may have some merit....
GLTAH.
My sentiment is a hold as I have enough exposure, but, for new players, have a crack - but it could be a wild ride.
DYOR.
Ann: Positive Phase 1 MEND Study Top-Line Results, page-145
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |